Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier.
1. A method of treating a carcinoma or melanoma in a subject in need thereof, wherein the subject has been diagnosed with the carcinoma or melanoma, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
so as to treat the carcinoma or melanoma.
2. A method of inhibiting a carcinoma or melanoma in a subject in need thereof, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
so as to inhibit the carcinoma or melanoma.
3. A method of obtaining beneficial results in a subject with a carcinoma or melanoma, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
so as to obtain beneficial results in the subject.
4. A method of lessening or alleviating the severity of a carcinoma or melanoma in a subject, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
so as to lessen or alleviate the severity of the carcinoma or melanoma.
5. A method of slowing down a carcinoma or melanoma in a subject, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject,
so as to slow down a carcinoma or melanoma.
6. A method of reducing the tumor size of a carcinoma or melanoma in a subject, consisting essentially of:
providing an mTOR inhibitor, wherein the mTOR inhibitor is selected from the group consisting of (i) temsirolimus (CCI-779) or a pharmaceutical equivalent, analog, derivative or a salt thereof, (ii) Everolimus (RAD001) or a pharmaceutical equivalent, analog, derivative or a salt thereof, and (iii) Rapamycin or a pharmaceutical equivalent, analog, derivative or a salt thereof;
providing an anti-CD4 antibody or an antigen-binding fragment thereof;
administering a therapeutically effective amount of the mTOR inhibitor to the subject; and
administering a therapeutically effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof to the subject, so as to reduce the tumor size of the carcinoma or melanoma.
7. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the mTOR inhibitor and the anti-CD4 antibody or an antigen-binding fragment thereof are administered concurrently.
8. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the mTOR inhibitor and the anti-CD4 antibody or an antigen-binding fragment thereof are administered sequentially.
9. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the anti-CD4 antibody is a monoclonal antibody or an antigen-binding fragment thereof, a polyclonal antibody or an antigen-binding fragment thereof, a chimeric antibody, a humanized antibody, a human antibody or a single chain antibody.
10. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the anti-CD4 antibody is a humanized anti-CD4 antibody.
11. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the anti-CD4 antibody is zanolimumab.
12. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the carcinoma is a renal cell carcinoma.
13. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the effective amount of the mTOR inhibitor is 0.1-0.5 mg/day, 0.5-1.0 mg/day, 1.0-1.5 mg/day, 1.5-2 mg/day, 2.0-2.5 mg/day, 2.5-5 mg/day, 5-10 mg/day, 10-15 mg/day, 15-20 mg/day, 20-25 mg/day, 25-30 mg/day, 30-35 mg/day, 35-40 mg/day, 40-45 mg/day, 45-50 mg/day, 50-55 mg/day, 55-60 mg/day, 60-65 mg/day, 65-70 mg/day, 70-75 mg/day, 75-80 mg/day, 80-85 mg/day, 85-90 mg/day, 90-95 mg/day or 95-100 mg/day.
14. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the effective amount of the anti-CD4 antibody or an antigen-binding fragment thereof is 100-200 mg/day, 200-300 mg/day, 300-400 mg/day, 400-500 mg/day, 500-600 mg/day, 600-700 mg/day, 700-800 mg/day, 800-900 mg/day, 900-1000 mg/day, 1000-1100 mg/day, 1100-1200 mg/day, 1200-1300 mg/day, 1300-1400 mg/day, 1400-1500 mg/day, 1500-1600 mg/day, 1600-1700 mg/day, 1700-1800 mg/day, 1800-1900 mg/day or 1900-2000 mg/day.
15. The method of claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the mTOR inhibitor and/or the anti-CD4 antibody or an antigen-binding fragment thereof is administered intravenously, intramuscularly, intraperitoneally, orally or via inhalation.